This webinar has been cancelled due to unforeseen circumstances. Thank you for your interest.
If you have questions please contact us.
Webinar Overview
Designing the right bioanalytical strategy for your antibody-drug conjugates (ADCs) can have a positive impact on timelines, costs, and reduce risk. However, between monitoring drug‑to‑antibody ratio (DAR) and understanding conjugation heterogeneity and in vivo stability, meeting regulatory expectations can be difficult.
This webinar will examine LC‑MS bioanalytical approaches and how they can be applied to generate both quantitative and structural insight across preclinical and clinical development. You’ll learn how targeted LC‑MS assays using triple-quadrupole instruments and high‑resolution mass spectrometry (HRMS) work in harmony to support more informed decisions throughout the ADC lifecycle.
Through practical examples, the session will demonstrate how these tools:
- Track DAR and ADC integrity over time
- Evaluate biotransformation and stability in vivo
- Confidently support both regulatory and non-regulatory studies
Webinar Presenter
Jordane Biarc
Chromatography – Team Leader
Charles River
Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.